Amakem Therapeutics has presented top-line results from two studies for AMA0076 for the treatment of glaucoma at the Ophthalmology Innovation Summit (OIS) at the 2013 Annual Meeting of the American Academy of Ophthalmology. The results detailed a first-in-human study in patients with glaucoma and ocular hypertension and a Phase Ib formulation study in healthy volunteers. AMA0076 is a highly potent locally-acting Rho Kinase (ROCK) inhibitor that has been designed to reduce intraocular pressure (...